Lead Product(s) : CG200745,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CG Pharmaceuticals Announces the Commencement of Phase 2 Study for Metastatic Pancreatic Cancer
Details : Ivaltinostat is a novel anticancer therapeutic candidate that inhibits enzymatic activity of histone deacetylase. It is being developed for the treatment of metastatic pancreatic ductal adenocarcinoma.
Product Name : CG200745
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2023
Lead Product(s) : CG200745,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable